LungLife AI, Inc. (GB:LLAI) has released an update.
LungLife AI, Inc. has announced a significant milestone in its commercialization efforts as its LungLB® blood-based test for lung cancer has been validated and published in the peer-reviewed journal BMC Pulmonary Medicine. The publication confirms the test’s analytical performance and is a key step toward Medicare reimbursement, crucial for broader patient access. Endorsed by experts, the test is celebrated for its reliability and utility in routine clinical settings, marking a major advance in early lung cancer detection.
For further insights into GB:LLAI stock, check out TipRanks’ Stock Analysis page.
